TY - GEN
T1 - An in-silico approach for drug repositioning to tumour anti-migration using an integrated genomic strategy
AU - Mao, Yong
AU - Cui, Kemi
AU - Lulu, Wang
AU - Zhao, Hong
AU - Nie, Fang
AU - Brandl, Miriam
AU - Beck, Dominik
AU - Gao, Liang
AU - Wong, Stephen
PY - 2011
Y1 - 2011
N2 - Cell migration is a key step for deterioration of many in situ or metastasis malignant tumours. Tumour anti-migration is a promising strategy to treat cancer, but corresponding drugs developed under such a strategy are still in dire poverty, partly due to the lengthly process of drug trials and approval required by the US Food and Drug Administration (FDA). Given there are thousands of FDA approved drugs in the market, we believe that drug repositioning may provide a fast and cost-effective way to identify potential anti-migration drugs. In this paper, an in-silico drug screening method using a genomic strategy is proposed for the goal, in which genomic signature identification combined with support vector machine modelling is adopted to estimate drug efficacy. And a high-throughput, sensitive, 3-dimensional invasion assay by quantitative bioluminescence imaging proved the performance of proposed method on in vitro disease models.
AB - Cell migration is a key step for deterioration of many in situ or metastasis malignant tumours. Tumour anti-migration is a promising strategy to treat cancer, but corresponding drugs developed under such a strategy are still in dire poverty, partly due to the lengthly process of drug trials and approval required by the US Food and Drug Administration (FDA). Given there are thousands of FDA approved drugs in the market, we believe that drug repositioning may provide a fast and cost-effective way to identify potential anti-migration drugs. In this paper, an in-silico drug screening method using a genomic strategy is proposed for the goal, in which genomic signature identification combined with support vector machine modelling is adopted to estimate drug efficacy. And a high-throughput, sensitive, 3-dimensional invasion assay by quantitative bioluminescence imaging proved the performance of proposed method on in vitro disease models.
UR - http://www.scopus.com/inward/record.url?scp=79956141276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956141276&partnerID=8YFLogxK
U2 - 10.1109/LISSA.2011.5754163
DO - 10.1109/LISSA.2011.5754163
M3 - Conference contribution
AN - SCOPUS:79956141276
SN - 9781457704208
T3 - Proceedings of the 2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011
SP - 88
EP - 91
BT - Proceedings of the 2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011
T2 - 2011 IEEE/NIH Life Science Systems and Applications Workshop, LiSSA 2011
Y2 - 7 April 2011 through 8 April 2011
ER -